Pliant Therapeutics (PLRX) CFO awarded 400,000 stock options at $1.30

Q: What are the key terms of the new stock option for the PLRX CFO?

The stock option gives the CFO the right to buy 400,000 shares of common stock at an exercise price of $1.30 per share , with an expiration date of January 22, 2036 .

Q: How do the newly granted Pliant Therapeutics (PLRX) options vest?

The filing states that 1/48th of the shares under the option vest in substantially equal monthly installments on each monthly anniversary of January 1, 2026 , as long as the CFO remains in continuous service.

Q: How many derivative securities does the PLRX CFO hold after this Form 4 transaction?

After the reported grant, the CFO beneficially owns 400,000 stock options directly.

Q: Was this Pliant Therapeutics (PLRX) Form 4 a purchase or a grant?

The Form 4 shows a stock option grant , coded as transaction type A (award), with a reported price of $0 for the derivative security itself and an exercise price of $1.30 per share for the underlying common stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Pliant Therapeutics reported that its Chief Financial Officer, Keith Lamont Cummings, received a new stock option grant. The option allows him to buy 400,000 shares of common stock at an exercise price of $1.30 per share, expiring on January 22, 2036. According to the vesting terms, 1/48th of the shares vest and become exercisable on each monthly anniversary of January 1, 2026, as long as he continues to serve the company. After this award, he holds 400,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cummings Keith Lamont

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	400,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 400,000 shares (Direct)

Footnotes (1)

[object Object]

Form 4 Insider Transactions: What Each Field Means →

01/26/2026 - 04:36 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cummings Keith Lamont

(Last)

(First)

(Middle)

C/O PLIANT THERAPEUTICS, INC.

331 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.3	01/22/2026		A		400,000		⁽¹⁾	01/22/2036	Common Stock	400,000	$0	400,000	D

Explanation of Responses:

1. 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

	/s/ Jennifer Woo, attorney-in-fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Pliant Therapeutics (PLRX) disclose?

Pliant Therapeutics disclosed that its Chief Financial Officer, Keith Lamont Cummings, received a grant of 400,000 stock options on January 22, 2026.

What are the key terms of the new stock option for the PLRX CFO?

The stock option gives the CFO the right to buy 400,000 shares of common stock at an exercise price of $1.30 per share, with an expiration date of January 22, 2036.

How do the newly granted Pliant Therapeutics (PLRX) options vest?

The filing states that 1/48th of the shares under the option vest in substantially equal monthly installments on each monthly anniversary of January 1, 2026, as long as the CFO remains in continuous service.

How many derivative securities does the PLRX CFO hold after this Form 4 transaction?

After the reported grant, the CFO beneficially owns 400,000 stock options directly.

Was this Pliant Therapeutics (PLRX) Form 4 a purchase or a grant?

The Form 4 shows a stock option grant, coded as transaction type A (award), with a reported price of $0 for the derivative security itself and an exercise price of $1.30 per share for the underlying common stock.